Please wait while the formulary information is being retrieved.
GRANIX (tbo-filgrastim)
- Chemotherapy-induced neutropenia
- Prevention of neutropenia from cancer chemotherapy
300 mcg/0.5 mL subcutaneous syringe
- Inject 5 mcg/kg by subcutaneous route once daily in abdomen, thigh, upper outer area of buttocks, or outer area of upper arm (rotate site)
480 mcg/0.8 mL subcutaneous syringe
- Inject 5 mcg/kg by subcutaneous route once daily in abdomen, thigh, upper outer area of buttocks, or outer area of upper arm (rotate site)
300 mcg/mL subcutaneous solution
- Inject 5 mcg/kg by subcutaneous route once daily in abdomen, thigh, upper outer area of buttocks, or outer area of upper arm (rotate site)
480 mcg/1.6 mL subcutaneous solution
- Inject 5 mcg/kg by subcutaneous route once daily in abdomen, thigh, upper outer area of buttocks, or outer area of upper arm (rotate site)
Chemotherapy-induced neutropenia
- Inject 5 mcg/kg by subcutaneous route once daily in the abdomen, thighs, upper outer areas of buttocks, or outer area of upper arms rotating injection sites
- Inject 5 mcg/kg by subcutaneous route once daily in abdomen, thigh, upper outer area of buttocks, or outer area of upper arm (rotate site)
Prevention of neutropenia from cancer chemotherapy
- Inject 5 mcg/kg by subcutaneous route once daily in the abdomen, thighs, upper outer areas of buttocks, or outer area of upper arms rotating injection sites
- Inject 5 mcg/kg by subcutaneous route once daily in abdomen, thigh, upper outer area of buttocks, or outer area of upper arm (rotate site)
- None
Contraindicated
- None
Severe
Moderate
- Hycamtin
- topotecan
- None
Contraindicated
- Acute respiratory distress syndrome
- Glomerulonephritis
- Nontraumatic splenic rupture
- Sickle cell disease
Severe
Moderate
- None
GRANIX (tbo-filgrastim)
- Chemotherapy-induced neutropenia
- Prevention of neutropenia from cancer chemotherapy
- None
- Arthralgias
- Bone pain
- Fever
- Headache disorder
- Hypesthesia
- Myalgias
- Nausea
- Pain
- Pruritus of skin
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Hypertension
- Injection site sequelae
- Leukocytosis
- Peritonitis
- Epistaxis
- Petechiae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory distress syndrome
- Alveolar hemorrhage
- Anaphylaxis
- Aortitis
- Capillary leak syndrome
- Cutaneous vasculitis
- Glomerulonephritis
- Hemoptysis
- Hepatomegaly
- Nontraumatic splenic rupture
- Osteoporosis
- Pulmonary hemorrhage
- Splenomegaly
- Supraventricular arrhythmias
- Sweet's syndrome
- Thrombocytopenic disorder
Less Severe
- Alopecia
- Diarrhea
- Drug-exacerbated psoriasis
- Fatigue
- General weakness
- Hematuria
- Proteinuria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Filgrastim
- Severity Level:
2
- Additional Notes: Insufficient human data; consider maternal treatment benefit
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Filgrastim
Poor oral bioavailability
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Poor oral bioavailability |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Chemotherapy-induced neutropenia | |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| 0-9 | A-Z |
|---|---|
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
Formulary Reference Tool